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ABSTRACT
Objective Evaluate the costs of offering non-invasive prenatal diagnosis (NIPD) for single gene disorders compared to
traditional invasive testing to inform NIPD implementation into clinical practice.
Method Total costs of diagnosis using NIPD or invasive testing pathways were compared for a representative set of
single gene disorders.
Results For autosomal dominant conditions, where NIPD molecular techniques are straightforward, NIPD cost £314
less than invasive testing. NIPD for autosomal recessive and X-linked conditions requires more complicated technical
approaches and total costs were more than invasive testing, e.g. NIPD for spinal muscular atrophy was £1090 more
than invasive testing. Impact of test uptake on costs was assessed using sickle cell disorder as an example. Anticipated
high uptake of NIPD resulted in an incremental cost of NIPD over invasive testing of £48 635 per 100 pregnancies at
risk of sickle cell disorder.
Conclusion Total costs of NIPD are dependent upon the complexity of the testing technique required. Anticipated
increased demand for testing may have economic implications for prenatal diagnostic services. Ethical issues
requiring further consideration are highlighted including directing resources to NIPD when used for information only
and restricting access to safe tests if it is not cost-effective to develop NIPD for rare conditions. © 2016 The Authors.
Prenatal Diagnosis published by John Wiley & Sons, Ltd.
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INTRODUCTION
Non-invasive prenatal diagnosis (NIPD) based on the analysis
of cell-free DNA (cfDNA) in maternal plasma is now available
in clinical practice for a small number of single gene disorders
and the potential to test for a wide range of conditions has
been demonstrated.1 NIPD allows parents with high risk
pregnancies the option of safer testing with a maternal blood
sample rather than invasive prenatal diagnosis that carries a
small miscarriage risk.2 Women who have used NIPD,3 carriers
of single gene disorders4–6 and health professionals7 welcome
the safety of NIPD and suggest uptake will be high with couples
using NIPD to prepare for the birth of an affected child as well
as to inform decisions about termination of pregnancy.
A key challenge for the development of cfDNA-based prenatal
tests is the low level of fetal cfDNA present alongside the high
background of maternal cfDNA in maternal plasma. In addition,
there are many different single gene disorders, each with their
own technical challenges for NIPD. The ﬁrst NIPD tests to enter
clinical practice have been for autosomal dominant conditions
that are paternally inherited or arise de novo such as
achondroplasia and thanatophoric dysplasia.8,9 In these cases
technical approaches are straightforward as the causative
mutation is not present in the mother, but could be present in
the fetus. NIPD has also been used for paternal exclusion in
autosomal recessive conditions where parents carry different
mutations, including congenital adrenal hyperplasia (CAH)10
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and cystic ﬁbrosis (CF).11 If NIPD detects the paternal mutation,
invasive testing is required to determine inheritance of the
maternal allele.10–12 The most technically difﬁcult NIPD tests are
for X-linked conditions or autosomal recessive conditions where
parents carry the same mutation, as the levels of the mother’s
alleles must be taken into account before accurate fetal diagnosis
can bemade. Using technologies such as digital PCR ormassively
parallel sequencing, which allow accurate quantiﬁcation of
speciﬁc sequences, proof-of-concept studies have been
performed using approaches such as relative mutation dosage
for beta thalasaemia13 and sickle cell disorder14 or analysis of
single-nucleotide polymorphisms (SNPs) by whole genome
sequencing and relative haplotype dosage analysis for beta-
thalasaemia15 andCAH.16 Practical limitations, such as estimation
of fetal fraction, that have prevented clinical implementation are
being addressed andNIPDwill soonbe available for a wider range
of conditions. It is important to note that NIPD for the direct
diagnosis of single gene disorders is used in high risk pregnancies,
either because of a family history or sonographic ﬁndings, and is
considered diagnostic. It can be considered a replacement for
invasive testing as, unlike non-invasive prenatal testing (NIPT)
for aneuploidy where conﬁned placental mosaicism or detection
of unexpected maternal chromosomal abnormalities may
confound results.17,18 These factors do not complicate prenatal
diagnosis for monogenic disorders, whether invasive or NIPD
based on analysis of cfDNA. Thus there is no need to conﬁrm
NIPD with invasive testing. When NIPD is performed for the
exclusion of paternal mutations, invasive testing is required for
deﬁnitive diagnosis if the paternalmutation is detected to conﬁrm
whether or not the maternal mutation has also been inherited.
Evaluation of the costs associated with implementing NIPD
into routine care is important to inform service delivery,
particularly in state funded healthcare such as the United
Kingdom’s (UK) National Health Service (NHS). A number of
studies have investigated the costs of introducing NIPT for
Down syndrome.19–22 Costs of offering NIPD for fetal sex
determination23 and NIPD for CF24 have also been explored,
but studies looking more broadly at the costs of NIPD for single
gene disorders have not been undertaken. Here we undertake
a preliminary assessment of the costs of offering NIPD for a
set of representative single gene disorders drawing comparison
to current invasive testing pathways.
Table 1 Characteristics of the single gene disorders included in the cost analysis
Condition NIPD approach Test characteristics
Inheritance: Autosomal dominant/de novo
Achondroplasia MPS Panel Maternal sample
Detects presence/absence of the main causative mutation and three additional mutations
Diagnostic test for male and female pregnancies
Currently offered in clinical practice in the UK
Thanatophoric dysplasia MPS Panel Maternal sample
Detects presence/absence of 14 possible causative mutations
Diagnostic test for male and female pregnancies
Currently offered in clinical practice in the UK
Inheritance: Autosomal recessive
Sickle cell disorder RMD Maternal and paternal sample
Fetal fraction estimate required for RMD analysis
Diagnostic test for male and female pregnancies
Congenital adrenal hyperplasia (CAH) RHDO Maternal, paternal and proband sample
As pseudogene present a proband sample is required to construct mutant alleles for RHDO
Fetal sexing ﬁrst, diagnostic test for female fetus only
Spinal muscular atrophy (SMA) RHDO Maternal, paternal and proband sample
As pseudogene present a proband sample is required to construct mutant alleles for RHDO
Diagnostic test for male and female pregnancies
Inheritance: X-linked
Haemophilia RMD Maternal sample
Fetal fraction estimate required for RMD
Fetal sexing ﬁrst, diagnostic test for male fetus only
Duchene Muscular Dystrophy (DMD) RHDO Maternal and proband sample required
As causative mutations have a high incidence of deletion/duplication plus 10% recombination
rate a proband sample is required to construct mutant alleles for RHDO
Fetal sexing ﬁrst, diagnostic test for male fetus only
MPS, massive parallel sequencing; RMD, relative mutation dosage; RHDO, relative haplotype dosage.
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METHODS
Representative single gene disorders
The conditions included in our cost analysis are described in
Table 1. Two autosomal dominant conditions were included:
achondroplasia and thanatophoric dysplasia. NIPD for these
conditions is available in clinical practice in the UK.9 Three
autosomal recessive conditions were included: sickle cell
disorder, CAH and spinal muscular atrophy (SMA). Sickle cell
disorder can be identiﬁed by NIPD using relative mutation
dosage, whilst for CAH and SMA relative haplotype dosage
analysis is required. As CAH is a sex linked condition and only
female fetuses are at risk of genital virilization, fetal sex
determination using NIPD would be performed followed by
diagnostic testing for female fetuses. Two X-linked conditions
were included: haemophilia and Duchene muscular dystrophy
(DMD). Haemophilia can be identiﬁed using relative mutation
dosage and DMD by relative haplotype dosage analysis. As
both conditions primarily affect males only, fetal sexing would
be performed followed by diagnostic testing for male fetuses.
Achondroplasia, thanatophoric dysplasia and haemophilia
can be diagnosed using a maternal blood sample only. All
other conditions require a paternal blood sample. Tests using
relative haplotype dosage analysis also require a proband
sample and NIPD could only be used if the family already
had a child with the condition or if samples were available
from grandparents for parental haplotype construction.25
Costs of NIPD versus invasive testing
Our perspective for the cost analysis was that of the prenatal
screening department of a local hospital in a cash-constrained
publicly funded health care system like the English NHS. We
considered a narrow range of costs, focusing on the costs of
the NIPD and invasive testing pathways only. We did not
include childbirth costs, or costs beyond childbirth such as
health care costs associated with looking after a child with a
single gene disorder as these are unlikely to be relevant for
the perspective taken. In addition lifetime costs for treatment
and care of children affected with single gene disorders are
not available in the UK, and inclusion of these costs requires
several complex assumptions about whether or not an affected
pregnancy is terminated, and whether or not a replacement
pregnancy follows termination. The total costs of diagnosis
using NIPD and invasive testing for each single gene disorder
were calculated. Input parameters are listed in Table 2.
Where possible local unit costs or published costs26,27 were
used. For conditions where NIPD is not yet available in clinical
practice, costs were estimated by our laboratory based on
current service costs and costs of consumables, equipment
and staff time derived from developing these tests in a research
setting. In the analysis two assumptions were made: (1)
invasive testing is not required to conﬁrm a positive NIPD
result, and (2) for sex-linked disorders fetal sex determination
using NIPD is performed as a ﬁrst step and diagnosis using
invasive testing or NIPD is only performed in 50% of cases
(female fetus for CAH, male fetus for haemophilia and DMD).
As the accuracy of NIPD for fetal sex determination is high
(99.5%), possible discordance was not factored into the
analysis.
Differences in uptake of NIPD versus invasive testing
Many parents are reluctant to undergo invasive testing for
prenatal diagnosis, mainly because of the small risk (0.5–1%)
of miscarriage related to the invasive procedure.2 Evidence
from questionnaire and interview based studies indicates that
the uptake of diagnostic testing may be higher if NIPD is
offered.3,4 To determine how differences in uptake would
inﬂuence total costs we used sickle cell disorder as an example
Table 2 Input parameters for the cost analysis
Parameter Value Source
Costs of invasive testing (all single gene disorders)
Molecular testing £370 Regional Genetics laboratory
Counselling, invasive test, sample transport, cytogenetics and feedback of results £650 Average cost from local fetal medicine units
Costs of NIPD
Fetal sex determination £275 Regional Genetics laboratory
Test for Achondroplasia £550 Regional Genetics laboratory
Test for Thanatophoric dysplasia £550 Regional Genetics laboratory
Test for Sickle cell disorder £1100 Estimation (Regional Genetics laboratory)
Test for Congenital adrenal hyperplasia (CAH) £2000 Estimation (Regional Genetics laboratory)
Test for Spinal muscular atrophy (SMA) £2000 Estimation (Regional Genetics laboratory)
Test for Haemophilia £1100 Estimation (Regional Genetics laboratory)
Test for Duchene Muscular Dystrophy (DMD) £1500 Estimation (Regional Genetics laboratory)
Pre-test counselling £70 Unit Costs of Health & Social Care 201426
Phlebotomy £3.42 NHS reference costs 2013–1427
Sample transport £5 Local fetal medicine unit
Feedback of results £28 Unit Costs of Health & Social Care 201426
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and calculated total costs of diagnostic testing using sickle cell
disorder in a population of 100 eligible pregnancies. Estimates
of uptake for testing with NIPD (95%) or invasive testing (if
NIPD was not available) (65%) were obtained from recent
research with carriers and affected adults with sickle cell
disorder (n = 64) recruited whilst waiting for a clinical
appointment at one London hospital (Hill et al. unpublished
data). In further sensitivity analyses we also varied uptake
and costs of invasive testing and NIPD in a scenario analyses
to check the robustness of the results. It was not possible to
perform this analysis for other conditions as reliable estimates
of uptake of NIPD or invasive testing were not available.
RESULTS
Costs of NIPD versus invasive testing
Costs of each component of invasive testing and NIPD, the
total costs and the difference between NIPD and invasive
testing are presented in Table 3. Total cost of invasive testing
was £1020 for most conditions, but lower (£793) when fetal
sex determination was performed as a ﬁrst step. For
achondroplasia and thanatophoric dysplasia total costs of
NIPD were £706, which was £314 less than invasive testing.
NIPD for autosomal recessive conditions and X-linked
conditions was more expensive, for example sickle cell disorder
(£1210, £190 more than invasive testing), CAH (£1385, £591
more than invasive testing), SMA (£2110, £1090 more than
invasive testing), haemophilia (£935, £141 more than invasive
testing) and DMD (£1135, £341 more than invasive testing).
Accounting for differences in uptake of NIPD versus invasive
testing
In 100 pregnancies at risk of sickle cell disorder we estimate
that 95 women would undergo NIPD compared with the 65
who would currently accept invasive testing. The total costs
of diagnostic testing for sickle cell disorder would increase
from £66 300 to £114 935 if NIPD was available (Table 4).
When we assumed an uptake of invasive testing as high as
95% or uptake of NIPD as low as 65%, the difference in total
costs between invasive testing and NIPD would be smaller
(£12 340 to £18 035) (Supporting Information—Table 1). The
costs per test performed did not have a large inﬂuence on
the results.
DISCUSSION
Offering NIPD for single gene disorders will have a signiﬁcant
impact on the costs of diagnostic pathways. For the autosomal
dominant conditions, achondroplasia and thanatophoric
dysplasia, which utilize the most straightforward technical
approaches, NIPD was £314 less than invasive testing. These
tests are available in clinical practice and current prices were
used in the analysis. Women who have had NIPD for skeletal
dysplasias have been extremely positive towards these tests
which are diagnostic, safe and can provide reassurance early
in pregnancy.3 For the autosomal recessive and X-linked
disorders, which require technically more difﬁcult approaches,
NIPD increases the costs of diagnostic testing pathways. NIPD
for these conditions is not yet available in clinical practice, so
costs were estimated by our laboratory based on current
Table 3 Costs of invasive testing, NIPD and differences in costs for each selected condition
Autosomal dominant Autosomal recessive X-linked
Achondroplasia
Thanatophoric
dysplasia
Sickle cell
disorder CAH SMA Haemophilia DMD
Invasive testing
Fetal sex determination (including phlebotomy and
sample transport)
— — — £283 — £283 £283
Counselling, invasive test, sample transport,
cytogenetics and feedback
£650 £650 £650 £325a £650 £325a £325a
Molecular test on amniocentesis or CVS sample £370 £370 £370 £185b £370 £185b £185b
Total invasive testing £1020 £1020 £1020 £793 £1020 £793 £793
NIPD
Fetal sex determination (including phlebotomy and
sample transport)
— — — £283 — £283 £283
Phlebotomy £3 £3 £7c £3c £7c £3c £3c
Sample transport £5 £5 £5 —b £5 —b —b
Counselling and feedback £98 £98 £98 £98 £98 £98 £98
Molecular test on maternal plasma sample £600 £600 £1100 £1000a £2000 £550a £750a
Total NIPD £706 £706 £1210 £1384 £2110 £935 £1135
Difference (NIPD-invasive testing) £314 £314 £190 £591 £1090 £141 £341
aWhen fetal sex determination is done as a ﬁrst step, the diagnostic test is only required in 50% of the samples.
bIncluded in fetal sex determination.
cMaternal and paternal sample required for NIPD, maternal samples already supplied if fetal sex determination performed.
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research setting costs. Costs of diagnostic pathways for sex-
linked conditions are reduced by using fetal sex determination
as a ﬁrst step. Previous work found that NIPD for fetal sex
determination itself was cost neutral for the NHS as the cost
of NIPD was balanced by the reduction in invasive testing.23,28
In cash-constrained publicly funded health care system such
as the English NHS decisions about the broad programme of
NIPD tests that could be offered are likely to be largely
dependent upon on their relative costs. The technical
difﬁculties of performing NIPD for autosomal recessive and
X-linked conditions are the primary reason NIPD is predicted
to be more expensive than invasive testing. Other factors
inﬂuencing NIPD costs include the number of cases and
opportunities to perform batch testing. For relatively common
conditions such as CF or sickle cell disorder batch testing may
lower costs. It may also be possible to test for several different
conditions and include multiple causative mutations in a
single assay. For example, testing for skeletal dysplasias in
our laboratory uses a massively parallel sequencing panel that
includes several conditions and multiple mutations.9 The large
number of different single gene disorders presents another
challenge for service delivery and costs for laboratories. For
rare single gene disorders there is a question as to the cost
and beneﬁts of developing NIPD when tests are performed so
infrequently, an issue that raises ethical concerns regarding
restricting access to safer testing.29 Our laboratory currently
offers a bespoke NIPD service for individual families at risk of
paternally inherited autosomal dominant conditions or
recessive conditions where parents carry different mutations.
Even in cases that involve simple molecular techniques and
the cost of the NIPD approach is relatively low, the overall cost
increases because of the time and consumable costs needed to
develop and validate NIPD for an individual family.
Ultimately, a signiﬁcant contributing factor to NIPD costs
relative to invasive testing will be test uptake as the safety
and ease of testing associated with NIPD means that uptake
is likely to be higher than for invasive testing and include many
couples that would not have previously considered prenatal
testing because of miscarriage risk from invasive testing. This
assumption is supported by research exploring the views of
women using NIPD for skeletal dysplasias3 and potential
service users who are carriers of single gene disorders.4–6 If this
is the case, more couples will undergo testing and total costs
will increase. Analysis of costs for sickle cell disorder in a
population of 100 eligible pregnancies suggests that NIPD
would be signiﬁcantly more expensive than invasive testing,
largely because of the predicted high uptake of NIPD. This is
comparable with our previous exploration of the cost of NIPD
for CF which found that a likely increased uptake of NIPD
(94.4%) compared to invasive testing (43.5%) would increase
overall costs.24 As hypothetical uptake of genetic tests can
differ from actual uptake, uptake and total costs must be
reassessed once NIPD for these disorders is available in clinical
practice. In addition, whilst our analysis shows that women
can have NIPD for the autosomal dominant conditions
achondroplasia and thanatophoric dysplasia at lower cost for
the NHS, this would only be the case if NIPD was generally
restricted to women who would have had invasive testing.
For achondroplasia and thanatophoric dysplasia total
numbers having prenatal testing may increase as women with
a previous affected pregnancy and a low recurrence risk may
chose NIPD, when in the past they would have declined
invasive testing because of miscarriage risk.3 In our laboratory
the total number of prenatal tests performed for
achondroplasia and thanatophoric dysplasia has steadily
increased following the introduction of NIPD in 2011/2012
(North East Thames Regional Genetics Laboratory–personal
communication); this increase is largely reﬂected in an
increase in the number of NIPD tests whilst invasive testing
rates have stayed the same or decreased (Supporting
Information—Table 2).
The expected increased uptake of NIPD over invasive testing
and the impact of on the cost of diagnostic pathways highlight
the ethical issues associated with using NIPD for information
only and the appropriateness of directing resources to a test
that would not change pregnancy management in state funded
health systems.30 Decisions about how NIPD is offered will
need to take this concern into consideration, keeping in mind
that decisions may vary from the couple’s initial intention
following receipt of results, as well as the clinical and
psychological beneﬁts afforded by NIPD which include early
the possibility of reassurance or provision of information for
planning and preparation of the birth of an affected child, as
well as the potential of access to surgical termination of
pregnancy.3,4
Study limitations
The main uncertainties in our analyses were NIPD uptake in
clinical practice and test costs, both of which have been
estimated. Costs may change when NIPD enters clinical
practice, for example costs may fall if volume increases. In
addition, we assumed 50% of couples with pregnancies at risk
of sex-linked conditions would go on to diagnostic testing
following fetal sex determination. In clinical practice this ﬁgure
Table 4 Total costs of invasive testing versus NIPD for sickle cell disorder in a population of 100 eligible pregnancies, including uptake
of testing
Parameter Invasive testing NIPD
Number of eligible pregnancies 100 100
Number taking up the test 65 95
Total costs per test performed £1020 £1210
Total costs per 100 pregnancies £66 300 £114 935
Additional costs for NIPD compared to invasive testing — £48 635
T. I. Verhoef et al.640
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may vary. For example, our UK audit of NIPD for fetal sex
determination found that invasive testing was performed in
46% of referrals for DMD (n = 92), 33% of referrals for CAH
(n = 61) and 16.1% of referrals for haemophilia (n = 112). Care
pathways may also change when NIPD is introduced, but
major changes are unlikely as both service users and providers
emphasize the need for NIPD to be offered through genetics
services.4,7,31 Another potential limitation is our narrow costing
perspective, which meant that we did not consider costs
beyond the delivery of the prenatal diagnostic service.
However, this perspective was selected as it is likely to be
highly relevant for decision makers considering implementing
NIPD for single gene disorders in the English the NHS. The
population based cost analysis for sickle cell disorder included
an estimate of test uptake derived from a questionnaire study
conducted in one London hospital and may not be
generalizable to a wider population. Furthermore, as the
questions on test uptake were hypothetical, choices may vary
from those made in real life.
Further research is needed to investigate the costs associated
with NIPD for individual conditions as they enter clinical
practice and the broader implications for service programmes.
Over time with increasing implementation of NIPD more data
will become available on test uptake and pregnancy outcomes
in clinical practice, including miscarriages averted. This
analysis should be then be repeated to deliver a cost-
effectiveness or cost-consequences analysis of NIPD for single
gene disorders in clinical practice. Until then, the work we
present here highlights some of the issues that may arise and
we suggest that careful audit of any NIPD service should be
put in place from the outset in order to collect the data
required to address these issues.
CONCLUSION
We have explored the costs of NIPD for a range of single gene
disorders, for some disorders NIPD is considerably cheaper
than invasive testing, but for conditions requiring more
technically challenging approaches costs were greater.
Moreover, the likely increase in uptake when NIPD becomes
available will be a major contributing factor to the cost of
prenatal diagnostic services. These ﬁndings highlight the need
for prospective consideration of both the economic issues that
may arise as more tests are developed, as well as the ethical
aspects around the potential for an increase in the number of
couples choosing NIPD for information only.
WHAT’S ALREADY KNOWN ABOUT THIS TOPIC?
• Non-invasive prenatal diagnosis (NIPD) for some single gene
disorders has entered clinical practice and NIPD for other
conditions is in development.
• Studies exploring the costs and beneﬁts of implementing NIPD for a
range of single gene disorders have not been undertaken.
WHAT DOES THIS STUDY ADD?
• For single gene disorders where technical approaches are
straightforward, NIPD was considerably cheaper than invasive
testing, but for conditions that need more technically challenging
approaches NIPD was more expensive.
• The anticipated increase in test uptake following the introduction of
NIPD will be a major contributing factor to the cost of a genetic
service offering prenatal diagnosis for single gene disorders in
clinical practice.
• Prospective monitoring and audit of uptake following clinical
implementation is required to allow full consideration of the
economic, social and ethical issues that will arise.
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